DEF 14A: Maravai LifeSciences Holdings Sets Date for 2024 Annual Shareholder Meeting

Maravai LifeSciences Holdings will hold its 2024 Annual Meeting of Shareholders virtually on May 23, 2024, to vote on director elections, auditor ratification, executive compensation, and other business.

Summary

• Maravai LifeSciences Holdings, Inc. will hold its 2024 Annual Meeting of Shareholders virtually on May 23, 2024, at 2:30 p.m. Pacific Time.
• Shareholders of record as of March 25, 2024, are entitled to vote.
• The meeting will address the election of four directors, ratification of Ernst & Young LLP as the independent auditor, an advisory vote on executive compensation, and other business.
• The Board recommends voting for the election of directors, ratification of the auditor, and approval of executive compensation.
• Shareholders can vote online, by phone, or by mail before the meeting.
• The proxy statement was first delivered to shareholders on or about April 25, 2024.
• As of the record date, Maravai had approximately 132,654,801 shares of Class A common stock and 119,094,026 shares of Class B common stock outstanding.

Sentiment

Score: 7

Explanation: The document is a standard corporate communication, presenting factual information in a neutral tone. The positive score reflects the routine nature of the announcements and the absence of overtly negative information.

Positives

• The Board recommends voting FOR the election of each director nominee.
• The Board recommends voting FOR the ratification of Ernst & Young as the independent auditor.
• The Board recommends voting FOR the approval of the compensation of named executive officers.
• The virtual meeting format provides ease of access and cost savings for shareholders and the company.

Future Outlook

The Board and Compensation Committee will review voting results on executive compensation when considering future decisions.

Management Comments

• William Trey Martin, III, Chief Executive Officer, encourages shareholders to vote their shares as soon as possible.
• The Board believes that the mix of experienced independent directors, as well as the GTCR-affiliated directors and our Executive Chairman, that currently comprise the Board, together with the structure and composition of the Board committees, provides strong overall risk oversight and strategic direction for the Company, benefitting Maravai and all of its shareholders.

Industry Context

The document provides insight into Maravai's corporate governance practices, aligning with industry standards for publicly traded companies. It details the composition and responsibilities of the Board and its committees, as well as the compensation structure for executive officers.

Comparison to Industry Standards

• The document details Maravai's corporate governance structure, which includes a classified board and various committees such as the Audit Committee, Compensation and Leadership Development Committee, and Nominating, Governance and Risk Committee.
• The document mentions that Maravai is a controlled company under Nasdaq rules due to GTCR's majority ownership, which allows it to be exempt from certain corporate governance requirements.
• The document outlines the compensation philosophy and objectives, which include aligning with long-term shareholder interests, competitiveness, motivating achievement of financial goals, rewarding superior performance, and responding to change.
• The document provides details on the compensation elements for NEOs, including base salaries, bonuses, and equity awards.
• The document mentions the use of a peer group to benchmark executive compensation, which is a common practice among publicly traded companies.
• The document describes the process for setting executive compensation, including the roles of the Compensation Committee, independent compensation consultant, and CEO.
• The document outlines the policies for approval of related party transactions, which is a standard corporate governance practice to ensure transparency and fairness.
• The document includes information on the security ownership of certain beneficial owners and management, which is a standard disclosure in proxy statements.
• The document provides details on the appointment of the independent registered public accounting firm and the fees for audit and other services.
• The document includes an Audit Committee Report, which is a standard component of proxy statements.
• The document provides information on delinquent Section 16(a) reports, which is a regulatory requirement for reporting insider transactions.
• The document includes a proposal for an advisory vote on the compensation of named executive officers, which is a requirement under Section 14A of the Exchange Act.
• The document provides information on where to find additional information, availability of SEC filings, code of ethics, and committee charters, which is a standard disclosure in proxy statements.

Related Party Transactions

• The company is party to a Tax Receivable Agreement with MLSH 1 and MLSH 2 that provides for the payment from time to time by us to MLSH 1 and MLSH 2, collectively, of 85% of the amount of the benefits, if any, that we realize or, under certain circumstances, are deemed to realize as a result of (i) certain increases in the tax basis of assets of Topco LLC and its subsidiaries resulting from purchases or exchanges of LLC Units, (ii) certain tax attributes of certain of the entities through which GTCR and other existing members of MLSH 1 and MLSH 2 held their ownership interests in MLSH 1, Topco LLC and subsidiaries of Topco LLC that existed prior to our initial public offering and (iii) certain other tax benefits related to our entering into the TRA, including tax benefits attributable to payments that we make under the TRA.
• On January 18, 2023, the Company acquired all of the outstanding membership interests in Alphazyme LLC (Alphazyme).
• On January 19, 2023, the Company entered into a Contribution Agreement with Alphazyme Holdings, Inc., a wholly owned subsidiary of the Company (Alphazyme Holdings), pursuant to which the Company contributed all such membership interests in Alphazyme (the Alphazyme Membership Interest) to Alphazyme Holdings.
• On January 22, 2023, Alphazyme Holdings entered into a Contribution and Exchange Agreement with Topco LLC, pursuant to which it contributed all of the Alphazyme Membership Interests to Topco LLC in exchange for 5,059,134 newly-issued LLC Units of Topco LLC at a price per unit of $13.87, which was equal to the 50-day volume-weighted average price of the Companys Class A common stock as calculated on January 18, 2023 (the Contribution and Exchange).
• Immediately following the Contribution and Exchange, the Company entered into a Forfeiture Agreement with Alphazyme Holdings, Topco LLC and MLSH 1, a related party, pursuant to which (i) each of the Company (together with Alphazyme Holdings) and MLSH 1 agreed to forfeit 5,059,134 and 4,871,970 LLC Units, respectively, representing 3.7% of the Companys (together with Alphazyme Holdings) and MLSH 1s respective LLC Units of Topco LLC, and (ii) MLSH 1 forfeited an equal number of shares of the Companys Class B common stock, in each case for no consideration.
• For more information on the Director Nomination Agreement that we are party to with GTCR, see the section of this proxy statement entitled Board of Directors and Corporate GovernanceDirector Nomination Agreement.
• We are party to a registration rights agreement with MLSH 1 and MLSH 2.
• During the fiscal year ended December 31, 2023, the Company paid approximately $27,800 to Curia Global, an affiliate of GTCR, for contract manufacturing and development services.
• During the same period, Curia Global paid approximately $108,500 to the Company for the purchase of CleanCap analogues.

Stakeholder Impact

• Shareholders are asked to vote on key decisions affecting the company's governance and executive compensation.
• Employees are indirectly affected by decisions on executive compensation and company performance.
• The outcome of the votes can influence investor confidence and the company's market value.

Next Steps

• Shareholders are urged to vote their shares as soon as possible.
• Attend the virtual Annual Meeting on May 23, 2024.
• Monitor the company's website for updates and additional information.

Key Dates

Keywords

Annual Meeting, Shareholders, Proxy Statement, Board of Directors, Executive Compensation, Ernst & Young, Director Election, Maravai LifeSciences